Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma
New England Journal of Medicine, 2015
Abstract
This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma 2018
- Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma 2021
- Hyperprogression and hypercalcemia after nivolumab treatment in three cases with renal cell carcinoma 2022
- Should we use combination therapy for all advanced renal cell carcinoma? 2019
- [Risk Classification and Nivolumab plus Ipilimumab Combination Therapy for Treatment of Renal Cell Carcinoma]. 2019
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 2014
- Karnofsky performance status revisited: reliability, validity, and guidelines. 1984
- Development and Validation of a Scale to Measure Disease-Related Symptoms of Kidney Cancer 2007
- Molecular mechanisms of T‐cell tolerance 2011